Virpax announces preliminary results of Probudur study with U.S. Army

Virpax Pharmaceuticals announced the initial results from the pilot study for Probudur performed by the U.S. Army Institute of Surgical Research USAISR under an existing Cooperative Research and Development Agreement CRADA . The USAISR is the U.S. Department of Defense’s premier research organization for developing solutions for trauma and critical care challenges in combat casualties. This study was designed to determine if Probudur reduces pain behaviors in a rat model of incisional pain. Two concentrations of Probudur were injected into the tissue around the incision site as well as a saline solution for the control group. Both doses of Probudur showed reduction in incision-induced pain behaviors. Probudur is being developed by Virpax to significantly reduce or eliminate the need for opioids after surgery or trauma in approved indications. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours.